Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs American Water Works Company Inc (AWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs American Water Works Company Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $285.17 (market cap $39.89B), while American Water Works Company Inc trades at $131.34 (market cap $25.52B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and American Water Works Company Inc pays a 2.74% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | AWK | |
|---|---|---|
Market Cap | $39.89B | $25.52B |
Sector | Health | Utilities |
52-Week High | $491.22 | $147.00 |
52-Week Low | $278.09 | $121.13 |
Enterprise Value | $38.15B | $41.08B |
Dividend Yield | — | 2.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
American Water Works (AWK) trades at $130.69, up 0.11% with a neutral technical outlook. The stock shows strong fundamentals with consistent revenue growth from $3.8B in 2022 to $5.1B in 2025, maintaining profit margins above 21%. Recent developments include infrastructure investments and regulatory approvals, while analyst consensus leans slightly bullish with a $137 price target.
AWK presents a stable investment opportunity with predictable utility earnings and dividend income. Key risks include regulatory rate approvals and capital expenditure requirements. The stock offers moderate upside potential with balanced analyst sentiment supporting long-term growth in essential water services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About American Water Works Company Inc
American Water Works is the largest investor-owned U.S. water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's only nonregulated business is water services for military bases, which operates under long-term contracts.
Read more on AWK →
